Trastuzumab-rezetecan for breast cancer with HER2 protein
Part of Cancer clinical trials.
This trial tests a new drug, Trastuzumab-rezetecan, in people with breast cancer that has a certain amount of a protein called HER2. It aims to see if the drug works and is safe for patients who are able to receive it before or after surgery, or for those whose cancer has spread and has been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with breast cancer that shows a certain level of a protein called HER2 (either high or low).
- You may be treated before surgery, after surgery, or for advanced breast cancer that has spread.
- If you have advanced breast cancer, you must have already tried at least one other treatment that stopped working.
- You should be able to take care of most daily tasks (score 0 to 2 on a simple scale).
- Women who can become pregnant must have a negative pregnancy test and use effective birth control during the study and for one year after the last dose.
- You cannot be in another clinical trial and must agree to follow the study schedule and procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody-drug combination (trastuzumab rezetecan, also called T-DXd) for patients with HER2-positive breast cancer whose tumor did not fully disappear after initial chemotherapy. The goal is to see if this drug can reduce the risk of cancer coming back.
This trial tests a new drug called trastuzumab rezetecan given before surgery for early-stage HER2-positive breast cancer. It's designed for patients whose cancer doesn't respond well to standard HER2-targeted treatments.
This trial tests a drug for people with HER2-positive breast cancer that has spread to only a few places in the body (up to 5 spots). It aims to see if the treatment works well before starting stronger therapies.
This trial tests two targeted drugs, trastuzumab rezetecan and trastuzumab deruxtecan, to see which works better for HER2-positive breast cancer that has spread or cannot be removed by surgery. These drugs target the HER2 protein on cancer cells to slow or stop their growth.
This trial tests a new drug, trastuzumab rezetecan, for women with breast cancer that has come back or spread and cannot be removed by surgery. It's for those who haven't had chemotherapy for advanced disease but have tried hormone therapy and it stopped working.
This study tests a new drug called trastuzumab rezetecan for people with advanced solid tumors that show a certain protein (HER2). The drug targets HER2 to help kill cancer cells, and the goal is to see if it is safe and effective.
Hear when a new HER2-low Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.